THERESA OKEREKE: Open Payments
NPI 1225454937 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,012 in 27 payments from 14 companies in 2025. Trend: 2023 $435 · 2024 $978 · 2025 $1,012
Food & beverage: $1,012
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 6 | $232 |
| Lilly USA, LLC | 4 | $157 |
| Corcept Therapeutics | 2 | $153 |
| ABBVIE INC. | 3 | $138 |
| Axsome Therapeutics, Inc. | 1 | $96 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $54 |
| Amgen Inc. | 2 | $39 |
| Dexcom, Inc. | 1 | $25 |
| AstraZeneca Pharmaceuticals LP | 1 | $22 |
| Bayer Healthcare Pharmaceuticals Inc. | 1 | $22 |
Products named: Korlym, ZEPBOUND, Auvelity, QULIPTA, JARDIANCE, VRAYLAR, EVENITY, Wegovy.
Industry payments across MD — which companies pay providers there.
